Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J
. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228.
PMC: 4484602.
DOI: 10.1016/j.cell.2015.05.001.
View
2.
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M
. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57.
PMC: 3641696.
DOI: 10.1200/JCO.2012.43.1882.
View
3.
Nizialek E, Antonarakis E
. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Cancer Manag Res. 2020; 12:8105-8114.
PMC: 7489946.
DOI: 10.2147/CMAR.S227033.
View
4.
Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N
. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open. 2020; 3(10):e2021692.
PMC: 7593810.
DOI: 10.1001/jamanetworkopen.2020.21692.
View
5.
Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E
. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Ann Oncol. 2012; 23(11):2943-2947.
DOI: 10.1093/annonc/mds119.
View